American Association for Cancer Research (AACR): Annual Meeting 2013


Published on

  • Be the first to comment

  • Be the first to like this

American Association for Cancer Research (AACR): Annual Meeting 2013

  1. 1. 13AM_CFA_covers_Layout 1 8/29/12 11:10 AM Page 2 C A L L F O R A B S T R A C T S ANNUAL MEETING 2013 “Personalizing Cancer Care Through Discovery Science” April 6-10, 2013 Walter E. Washington Convention Center Washington, DC Abstract Submission Deadline: November 15, 2012
  2. 2. 13AM_CFA_covers_Layout 1 8/28/12 12:40 PM Page 3 ANNuAl MEETiNg 2013 PRogRAM, EDuCATioN, AND ExhibiTS CoMMiTTEES 2013 AACR Annual Program Committee Thomas F. Gajewski Kohei Miyazono Meeting Scientific Members Maura L. Gillison Robert A. Mook, Jr. Program Committee Angelika B. Amon William M. Grady Stephen D. Nimer Chairperson Samuel Aparicio Philip D. Greenberg Garry P. Nolan Carlos L. Arteaga Sean Grimmond Ramon E. Parsons José Baselga Laura D. Attardi Kristian Helin Charles M. Perou Alberto Bardelli James G. Herman Kornelia Polyak Co-Chairpersons Dafna Bar-Sagi Thomas J. Hudson Neal Rosen Cory Abate-Shen Nina Bhardwaj Patrick Humbert Martine F. Roussel James P. Allison Jean-Yves Blay Luisa Iruela-Arispe David M. Sabatini René Bernards Peter J. Campbell Peter K. Jackson Yardena Samuels James R. Cerhan Pasi A. Jänne Lewis C. Cantley Charles L. Sawyers Arul M. Chinnaiyan Randall S. Johnson Andrew J. Dannenberg Robert D. Schreiber Karen Cichowski Yibin Kang James R. Downing Kevin M. Shannon Ezra E. W. Cohen Michael B. Kastan Jeffrey A. Engelman Jerry W. Shay Joseph F. Costello Nicholas J. Keen Keith T. Flaherty Alice T. Shaw Tom Curran Thomas W. Kensler David B. Solit Peter W. Laird Riccardo Dalla-Favera Guido Kroemer Steven K. Davidsen Jin Soo Lee Margaret R. Spitz Michael J. Luzzio Johann S. de Bono John P. Leonard Kimberly Stegmaier Elaine Mardis Phillip A. Dennis Ross L. Levine Josep Tabernero Yusuke Nakamura Titia de Lange A. Thomas Look David E. Uehling William R. Sellers Matthew G. Vander Heiden Hugues de Thé Patricia M. LoRusso Phillip A. Sharp J. Alan Diehl Scott W. Lowe Laura J. van ‘t Veer M. Celeste Simon Brian J. Druker John M. Maris Karen H. Vousden Eileen P. White Stephen W. Fesik Wells A. Messersmith Timothy C. Wang Education Committee Education Committee Albert C. Lockhart Ralph Scully Co-Chairpersons Members David C. Lyden Kimberly D. Siegmund Lewis C. Cantley Ron Bose Cynthia X. Ma Nancy A. Speck Jeffrey A. Engelman James E. Bradner Ursula A. Matulonis Muneesh Tewari Peter W. Laird Robert J. Coffey, Jr. Ari M. Melnick David A. Tuveson Elaine Mardis Andrew J. Dannenberg Gordon B. Mills Cornelia M. Ulrich M. Celeste Simon Nancy E. Davidson Tony S. K. Mok Giske Ursin Keith T. Flaherty William G. Nelson Toshikazu Ushijima Elsa R. Flores Jacqueline Payton Matthew G. Vander Heiden Sanjiv Gambhir Helen M. Piwnica-Worms Robert H. Vonderheide Amato J. Giaccia Ellen Puré Karen H. Vousden Margaret A. Goodell Andrea L. Richardson Geoffrey M. Wahl Luisa Iruela-Arispe Sandra W. Ryeom Matthew J. Walter Kimberly J. Johnson Yardena Samuels Zena Werb Raghu Kalluri Chris Sander Kwok-Kin Wong Exhibits Committee Exhibits Committee Elizabeth A. Grimm Clinical Trials Committee Chairperson Members Patricia M. LoRusso Appointments pending Ethan Dmitrovsky Edward Chu Patricia S. Steeg Nicholas C. Dracopoli Chris Takimoto AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  3. 3. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 1 Table of Contents IFC AACR Annual Meeting 2013 Program, Education, and Exhibits Committees inside front cover 4 Letter from the President and Program Committee Chairperson 6-11 Program in Progress 6 Plenary Sessions 7 Major Symposia 8 Current Concepts Sessions 9 Forums and Meet-the-Expert Sessions 10 Professional Advancement Sessions 12-25 Guidelines for Preparation and Submission of Abstracts AACR Officers 12 What You Need to Submit an Abstract President Frank McCormick 13 Procedure for Submitting Abstracts President-Elect Charles L. Sawyers 14 Late-Breaking Abstracts Treasurer 16 Abstract Sponsorship Regulations William N. Hait Past President 18 Spotlight on Clinical Research Judy E. Garber Chief Executive Officer 20 Abstract Categories Margaret Foti 26 Membership Categories Board of Directors 27 Financial Support for Attendance Until 2013 Todd R. Golub 28 Housing Jennifer Rubin Grandis Sir David P. Lane 29 Travel Kornelia Polyak Owen N. Witte 30 AACRcentral Until 2014 Joan S. Brugge 32 Mobile Technology at the Annual Meeting Arul M. Chinnaiyan Thomas A. Sellers 33 Annual Meeting Print Publications Laura J. van ‘t Veer 34 Registration Kristiina Vuori Until 2015 37 Housing Form Kenneth C. Anderson Lewis C. Cantley 38 Hotel List Michelle M. Le Beau Benjamin G. Neel 40 Hotel Map Karen H. Vousden IBC General Information inside back cover 1
  4. 4. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 2 “Overall, theand should lead inspirational meeting was to many fruitful collaborations. Its a unique opportunity for the cancer research community to communicate ideas across cancer disciplines… ” 2 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  5. 5. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 3 Why You Should Attend It has been said around the world that the AACR Annual Meeting drives the cancer agenda. This meeting brings together the best and latest findings in all major areas of cancer research. Through plenary sessions, symposia, forums, educational sessions, methods workshops, poster presentations, conversations with experts, and networking, attendees walk away with a wealth of new information, more connections, and renewed energy, inspiration, and focus in their work. A past attendee notes: “Overall, the meeting was inspirational and should lead to many fruitful collaborations. Its a unique opportunity for the cancer research community to communicate ideas across cancer disciplines…” Last year, nearly 17,000 participants from 70 countries gathered to discuss over 6,100 abstracts and to hear invited presentations from 750 speakers on new and significant discoveries in basic science, translational research, clinical trials, and population sciences. The 2012 Annual Meeting featured: • 6,162 proffered papers presented in 210 poster sessions and 30 minisymposia • 267 sessions accredited for continuing medical education for a total of 45.5 AMA PRA Category 1 Credits™ • 50 educational sessions and methods workshops for those seeking a foundation of knowledge in rapidly developing areas • 14 professional advancement activities covering topics such as grant writing, getting your research published, and the mentor-mentee relationship • 843 webcasts of the scientific talks available to attendees and subscribers • 458 exhibiting companies in 779 booths at the exhibition • Over 21 trillion media impressions resulting from press coverage of hot topics in many major outlets including The Wall Street Journal, The New York Times, HealthDay, Yahoo! News, Associated Press, The Los Angeles Times, USA Today, U.S. News & World Report, Huffington Post, Gizmodo, Reuters, The Economist, and more What You Can’t Afford to Miss Be a part of the AACR Annual Meeting 2013 so you won’t miss: • The premier meeting in cancer research where you are among the best and the brightest in the cancer field from around the world • Participation in abstract submissions and presentations • The latest developments in basic science, translational research, clinical trials, and population sciences • Our online itinerary planner that allows you to search and schedule the topics, speakers, and posters that are of interest to you • A multitude of networking events and professional development activities, plus the annual Cancer and Biomedical Research Career Fair 3
  6. 6. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 4 Dear Members, Colleagues, and Friends of the AACR, It is our pleasure to announce and invite you to attend the 104th Annual Meeting of the American Association for Cancer Research, to be held April 6-10, 2013, in Washington, DC. As always, this AACR Annual Meeting will highlight the latest and most exciting discoveries in every area of cancer research, and it will provide a unique opportunity for investigators from all over the world to meet and interact. Being in Washington, DC, at this time will give us a special opportunity for our collective voices to be heard, and several sessions and events will emphasize the vital importance of reaffirming our Nation’s commitment to the conquest of cancer. The Annual Meeting scientific program will feature daily plenary sessions, major symposia, minisymposia, forums, educational sessions, methods workshops, poster sessions, “Meet-the-Expert” sessions, “Current Concepts in Organ Site Research” sessions, “Current Concepts in Diagnostics and Therapeutics” sessions, and an exciting new series of sessions focused on “Current Concepts in Epidemiology and Prevention.” Based on the huge success of last year’s sessions on cutting-edge, science-based clinical trials, we are again planning to hold several sessions featuring presentations of new data on cutting-edge clinical trials along with commentaries on the implications of these trials for improved patient care. We will also be featuring a poster session on “Clinical Trials in Progress.” In addition, for the second year, we are planning a track devoted to regulatory science and policy. This multidisciplinary program is being developed through the devoted efforts of our team of Co-Chairpersons, whose names are listed in this publication. Together, we are assembling an outstanding roster of speakers who will update participants on their latest research findings. Along with the hundreds of invited talks, we will feature over 6,000 proffered papers from researchers all over the world. We want to thank the Program Committee Co-Chairpersons for their incredible expertise and guidance in shaping an innovative program that will be enjoyable as well as educational. With the accelerating pace of discoveries in the basic, translational, and clinical sciences, due in large part to the advent of new technologies, cancer researchers are making rapid progress that is having significant patient benefit. It is clear that in the near future even greater opportunities for the prevention, management, and cures for all types of cancer will abound. We are confident that attending the AACR Annual Meeting will give you renewed energy, inspiration, and focus in your work. Please register early and submit your abstract by the November 15, 2012, deadline. We look forward to seeing you in Washington, DC. Sincerely, Frank McCormick, Ph.D., F.R.S., D.Sc. José Baselga, M.D., Ph.D. AACR President, 2012-2013 Chairperson, 2013 Program Committee 4 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  7. 7. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 5 5
  8. 8. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 6 PROgRAM iN PROgRESS On Saturday, April 6, 2013, a full program of Educational Sessions, Methods 2013 Workshops, Meet-the-Expert Sessions, and Award Lectures will be presented beginning at 8:00 a.m. The Opening Ceremony and Opening Plenary Session will take place on Sunday morning, April 7. The meeting will conclude on Wednesday, April 10. The 2013 Program in Progress follows. Regular updates to the program will be posted on the AACR website ( Plenary Sessions Opening Plenary Session Sunday, April 7, 2013 Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA Speakers: Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands Charles M. Perou, University of North Carolina at Chapel Hill, Chapel Hill, NC Siddhartha Mukherjee, Columbia University, New York, NY Additional speaker to be announced Epigenetics Chairperson to be announced Speakers: Peter W. Laird, University of Southern California, Los Angeles, CA Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA Robert A. Copeland, Epizyme, Inc., Cambridge, MA Cancer Evolution and Resistance Chairperson: Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA Speakers: Jeffrey A. Engelman Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands 6 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  9. 9. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 7 Major Symposia Adaptive Signaling in Resistance Imaging in Cancer Research Obesity, Energy Balance, and Metabolism The Bayard D. Clarkson Infections and Cancer: Symposium on Stem Cells Can We Cure Cancer Ras and Metabolism and Cancer: Stem Cell Biology Through Vaccinations? and Therapeutics The Ruth Sager Memorial Innate Sensing in the Tumor Symposium: Cancer Biological and Clinical Microenvironment Heterogeneity Implications of Premalignant Cancer Lesions The Interface Between The Stanley J. Korsmeyer Development and Cancer Using Memorial Symposium: Targeting Blood-Based Molecular Analysis Model Organisms Cell Death Pathways for Cancer of Cancer Therapy Large-Scale Genomic Studies of Context-Dependent Functions of Human Cancer Ras/Raf in Cancer Strategies to Overcoming Drug Resistance Metabolic and Epigenetic Developmental Pathways and Interactions in Cancer Cancer Stress Response Pathways in Cancer Metabolic Vulnerabilities of Emerging Technologies in Cancer Cells Cancer Research Synthetic Lethality and Its Discovery Expanding the Druggable Genome Mitotic Checkpoints Driving Cancer Therapeutic Strategies Target Validation by Chemical Genetic Mechanisms for Probes/Designer Chemical Resistance and the Mutations in Epigenetic Readers, Probes and Phenotypic Approach Implications/Resistance to Writers, and Erasers to Drug Discovery Targeted Therapies New Approaches to Genomic Characterization of Drug Discovery Targeting the Stroma Mouse Models New Vaccine Strategies Use of Next-Generation The Global Cancer Crisis: Needs Sequencing: Implementation of and Opportunities for Prevention Noncoding RNAs Clinical Genomics 7
  10. 10. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 8 PROgRAM iN PROgRESS 2013 Current Concepts in Current Concepts in Current Concepts in Organ Site Research Diagnostics and Epidemiology and Therapeutics Prevention Bone Metastasis Advances in Antibody-Drug Clinical Trials with Functional The Breast Cancer Genome Conjugates Foods and Its Implications for Therapy Classification and Aging, Telomeres, and Cancer Epigenetic Mechanisms of Pathogenesis of Liver Cancers Cancer Risk Avatar: Individualized Human Druggable Targets in Cancer Models in Mice Human Papillomavirus: Ewing’s Sarcoma Beyond Cervical Cancer Chemical Engineering of Emerging Targets in the Biologics Treatment of Lung Cancer Genomics-Driven Immune Epigenetic Mechanisms in Therapeutics Gastrointestinal Differentiation and Malignant Transformation Metformin, Diabetes, and Cancer Esophageal Cancer Next-Generation Therapeutic Genetic Determinants of Brain Modeling in Mice Metastasis Novel Mechanisms of Gynecologic Cancer Mutations Latent Metastasis Translational Research Lymphoid Malignancies Breakthroughs Melanoma Myeloid Malignancies Nervous System Tumors Pancreatic Adenocarcinoma Pediatric Tumors Prostate Cancer: The Dilemma of Overdiagnosis and Overtreatment Targeting Lymphoid Malignancies: Working from the Outside In 8 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  11. 11. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 9 Forums Cancer in the Adolescent and Young Adult Population Clinical Trials Based on Mutations versus Histology Circulating Tumor Cells versus Serum DNA Drug Discovery in Industry, Academia, and Government— What Is the Track Record? Genome-Wide Association Studies: What We Have Learned, Future Directions, Next Generation Human Variation and Its Impact on Drug Development The Role of Stroma in Pancreatic Cancer Stem Cells in Cancer The Utility of Cell Line Screens for Drug Sensitivities Meet-the-Expert Sessions Speakers to be announced 9
  12. 12. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 10 PROgRAM iN PROgRESS 2013 Professional Advancement Sessions Professional Advancement Sessions Advance registration is only by the Associate Member Council have long been an integral part of available for the Grant Writing will be announced. Each will be the AACR Annual Meeting Workshop. Participation for all other aimed towards the professional experience, representing our sessions is on a first-come, needs of Associate Members and dedication to the education, training, first-served basis, and space is nonmember graduate students, and career advancement of cancer limited. Nonmembers are required to medical students and residents, and researchers. Sessions are organized pay on site. clinical and postdoctoral fellows, to provide important skills to and will focus on topics of particular investigators at all levels, from high Professional Advancement Sessions interest to early-career scientists. school students to senior faculty. at the Annual Meeting 2013 will We invite you to participate in include the following, with more to Career Paths in Cancer Drug sessions that will enrich your career. be added soon. For session Development updates, visit Organized by the Chemistry in For AACR members, all 2013 Cancer Research Working Group Professional Advancement Sessions Careers in Clinical and (CICR) Young Chemists Committee are free with your Annual Meeting Translational Cancer Research registration (except for the Grant Roundtable Navigating the Road to a Successful Writing Workshop) and are an added Career in Cancer Research 16th Annual Grant Writing Workshop Organized by Minorities in Cancer benefit of your membership. Saturday, April 6, 2013 Research (MICR) For nonmembers, there is an 12:00 p.m. to 5:00 p.m. additional fee of $45 ($95 for the Organized by the Associate Member Career Mentoring Session Grant Writing Workshop) for Council (AMC) Organized by Women in Cancer attendance at each session. If you Research (WICR) This intensive half-day workshop are not an AACR member, we features keynote presentations, a Eighth Annual Undergraduate strongly encourage you to join and mock study section, and ample time Student Caucus and take advantage of the many benefits for roundtable discussions with Poster Competition of membership, which include senior scientists. This session is Organized by the AACR Science attendance at these sessions. aimed towards Associate Members Education Committee and nonmember graduate students, medical students and residents, and This exciting session gives clinical and postdoctoral fellows undergraduates the opportunity to with limited or no experience in learn more about current research preparing grant applications. Lunch in the cancer field, hear from will be provided. Preregistration is investigators about educational strongly encouraged; there is a pathways and career development, $45 registration fee for AACR explore career options in the cancer members and a $95 registration fee field, and compete for monetary for nonmembers. To register for the prizes while presenting their Grant Writing Workshop, check the research. Undergraduates at all appropriate box on the Official levels as well as postbaccalaureate Registration Form on page 35 or students are welcome to participate. register online beginning E-mail September 27, 2012. for more information. Visit to download Three additional Professional the registration form. Advancement Sessions organized 10 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  13. 13. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 11 Special Program for poster areas with mentors, and a High School Students: networking lunch. Local students The Conquest of Cancer and the and children and/or students of Next Generation of AACR members and of other Cancer Researchers Annual Meeting registrants are welcome to register. Visit This free, interactive program is to download designed to inspire students to the High School Program pursue careers in cancer research Registration Form. and the biomedical sciences. Students learn about cancer from the experts while interacting with scientists, physicians, and their peers. The program includes lectures, tours of the exhibits and Related Career Advancement Sessions Annual Career Fair Meet the Research Pioneer Career Conversations are The AACR 6th Annual Cancer and Biomedical sessions are organized by the informal networking and Research Career Fair will be held on Saturday, Associate Member Council (AMC) discussion sessions designed for April 6, 2013. Recruiters from academia, industry, and are intended for early-career early-career scientists. Sessions and government will meet and connect with scientists. These sessions provide take place in the Associate researchers and clinicians at all career levels. a special opportunity to meet Member Resource and Career The Career Fair is free to all job seekers. esteemed researchers in a small Center in AACRcentral and limited Recruiters will have free access to interview group setting to discuss their seating is available. Visit rooms during the 2013 Career Fair and career path and their vision for the for throughout the Annual Meeting. Please visit future of their particular field of session updates. for more information. interest. Last year’s speakers included Drs. Beverly A. Teicher, Hans Clevers, Lisa M. Coussens, and Jonathan D. Licht. Sessions will take place in the AACR Amphitheater in AACRcentral. For session updates, Limited seating is available on a first-come, first-served basis. visit 11
  14. 14. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 12 gUiDEliNES FOR PREPARATiON AND SUBMiSSiON OF ABSTRACTS What You Need to Submit an Abstract Before you submit your abstract a $60 abstract submission fee. You online at, will be asked to provide valid credit you must have the following: card information to cover payment of the fee, or you may send a check 1) Web Browser: Microsoft Internet to the address provided in the Explorer 7.0 or Higher. The AACR payment section of the Online Online Abstract Submission System Abstract Submission System has been optimized for use with the (include the Abstract Control newest features only available in Number on your check). Your Internet Explorer version 7.0. submission will not be complete (Download at until payment is verified. The submission fee is nonrefundable Browsers should be set to enable regardless of the final disposition of JavaScript and to accept cookies. the abstract. Receipts may be Users who need assistance in obtained by contacting the AACR at properly updating and configuring their browsers should contact Abstract Submission Customer 4) Financial Relationships of Service at (217) 398-1792 or Co-Authors. Per ACCME regulations, the AACR must collect information on the financial 2) Sponsor Permission and relationships of all meeting Information. Each abstract must be presenters and abstract authors. sponsored by an Active, Emeritus, You will be asked to disclose your Honorary, Associate, or Affilate financial relationships and the AACR member. You will be asked to financial relationships of all of your provide the name or member co-authors. For more information on number of the AACR member who financial relationships, visit has agreed to sponsor your abstract; you must secure the meetings–workshops/cme.aspx. permission of the sponsor before submitting the abstract. Each AACR 5) Abstract Category and member in good standing (dues Subclassification. You must select paid for the current year) may a category and subclassification sponsor one abstract. Please keep for your abstract. See pages 20-25 in mind that as a result of this for details. restriction, each abstract submitted must have a different member 6) Chemical Structure Statement. sponsor. For details, see the You will be asked to state whether “Abstract Sponsorship Regulations” chemical compounds were used to on page 16 of this Call for Abstracts. generate the data in the abstract and, if so, whether you intend to 3) Payment Information: disclose the chemical structure Submission Fee. Each abstract during your presentation at the submitted must be accompanied by meeting. 12 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  15. 15. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 13 Procedure for Submitting Abstracts AACR Online Abstract Length of Abstracts Abstract Deadline Submission System The combined length of the The deadline for abstract Authors must submit abstracts abstract body, title, and tables submissions is 11:59 p.m. for presentation at the Annual may not exceed 2,600 U.S. Eastern Time, Thursday, Meeting 2013 using the AACR characters, not including spaces November 15, 2012. Abstracts Online Abstract Submission and the author list. Tables count submitted in any form after the System, which will be available for 800 characters against the deadline will not be considered at limit. Submission cannot be by the Program Committee. beginning Monday October 1, completed for abstracts that 2012. You can create, modify, exceed this limit. Note: Submitting an abstract for and submit abstracts until the presentation at the AACR November 15, 2012, abstract Annual Meeting 2013 does not deadline. Complete instructions constitute registration for the Copyright Transfer/Permission meeting. Abstract presenters on the use of the AACR Online to Record/Abstract must register to attend the Abstract Submission System Presentation meeting by using the form will be provided on the website. enclosed in this publication or On behalf of all authors, the by registering online at corresponding author must Abstract Control Number agree to: The AACR will not be An Abstract Control Number will 1) Transfer copyright of the responsible for the acceptance be assigned to each abstract abstract to the AACR for and processing of revised submitted online and will be publication; abstracts that are not submitted listed on all e-mail in compliance with the posted 2) Grant the AACR permission to correspondence regarding the regulations. No changes may be record the audio portion (if abstract. Please refer to the made in abstracts after the any) of the abstract Abstract Control Number in any November 15, 2012, deadline. presentation and to collect all abstract communications. revenue from subsequent sales; and 3) Confirm that an author will attend the Annual Meeting to present the abstract. 13
  16. 16. 13AM_CFA_text_Layout 1 8/28/12 12:32 PM Page 14 gUiDEliNES FOR PREPARATiON AND SUBMiSSiON OF ABSTRACTS late-Breaking Abstracts Late-Breaking Abstract Deadline the abstract control number and title Failure to comply with these as well as an explanation of the regulations pertaining to abstract The deadline for late-breaking reason for withdrawal. presentation may result in actions abstracts is Monday, January 28, including: 2013. Abstracts detailing highly significant and timely findings in any • The withdrawal of the abstract area of cancer research that were Presentation of Abstracts at the from the session not available at the time of the AACR Annual Meeting regular abstract deadline will be • The removal of the abstract from Because the Proceedings of the the online Proceedings considered by the AACR Annual AACR is intended to represent a Meeting Program Committee for summary of all of the abstract • The loss of future sponsorship presentation at the AACR Annual presentations at the Annual privileges for the sponsor of the Meeting 2013. Only those abstracts Meeting, every abstract that has abstract that are deemed to be of high been accepted for publication in the scientific priority will be accepted. • The loss of future abstract Proceedings of the AACR must also be presented at the meeting. submission/authorship privileges A special subcommittee of the Specifically, the author listed as the for the presenter of the abstract Program Committee will evaluate the merit of late-breaking abstracts. presenter for an abstract Each late-breaking abstract must be submission must attend the session sponsored by an AACR member. in which the abstract is scheduled Abstract submission fees and to discuss in detail the research sponsorship regulations also apply outlined in the published abstract, to late-breaking abstracts. according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend Deadline for Withdrawal of the session to present the abstract, Abstracts he or she must contact the AACR Program Development Department The AACR cannot comply with any at (215) 440-9300 or request for withdrawal of an to designate a abstract that will delay the co-author to serve as the presenter. publication of the Proceedings. If no authors are available to present However, requests to withdraw the abstract, the presenter must abstracts will be accepted through withdraw the abstract immediately Friday, January 25, 2013. Requests by contacting the AACR Program to withdraw late-breaking abstracts Development Department. will be accepted through Wednesday, March 6, 2013. Withdrawal requests must sent by e-mail to Withdrawal requests must include 14 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  17. 17. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 15 15
  18. 18. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 16 gUiDEliNES FOR PREPARATiON AND SUBMiSSiON OF ABSTRACTS Abstract Sponsorship Regulations 1. Each abstract submitted for presentation 6. Permission to list an Active, Emeritus, or at the AACR Annual Meeting must be Honorary AACR member as a sponsor or sponsored by an Active, Emeritus, endorser must be obtained prior to Honorary, Associate, or Affiliate selecting the sponsor/endorser in the AACR member. Online Abstract Submission System. Individuals listed as sponsors or 2. Active, Emeritus, and Honorary members endorsers of abstracts will receive a may use their sponsorship privilege in one confirmation of sponsorship or of two ways: (a) the sponsor may be one endorsement via e-mail or fax. Sponsors of the authors of the abstract; or (b) the and endorsers are strongly encouraged to sponsor may use his or her privilege on review the confirmation e-mail or fax to behalf of the authors, who may be either ensure that the correct abstract title, members or nonmembers of AACR. author, etc., has been indicated. 3. An Associate or Affiliate Member in good 7. The sponsor is obligated to ascertain that standing may sponsor his or her own all authors are aware of and agree to the abstract provided that: (a) he or she is the content of the abstract. Sponsorship of presenter of the abstract; and (b) an an abstract implies support for the data Active, Emeritus, or Honorary Member in and the interpretations contained therein. good standing endorses the work. By Individuals who wish to apply for AACR endorsing an abstract, a member does not membership and sponsor their own lose his or her own sponsorship privilege. abstract must submit their complete application for membership no later than 4. The sponsor must be a member of AACR November 8, 2012 for regular abstracts in good standing. Membership dues must or by January 21, 2013, for late-breaking have been paid through the current year abstracts. Membership questions may be by the time of the submission of the directed to abstract in order for the member to serve as the sponsor of an abstract for the upcoming Annual Meeting. As Honorary and Emeritus members are exempt from COMPLIANCE WITH THESE the payment of dues, this regulation does REGULATIONS IS THE RESPONSIBILITY not apply to them. Student members are OF THE AUTHORS. Adherence to these not eligible to sponsor an abstract. rules will be strictly enforced. Violations will result in the rejection of the abstract by the 5. Each member of AACR may sponsor one Program Committee. abstract for the November 15, 2012, regular deadline and one abstract for the January 28, 2013, late-breaking deadline. (Members must have their 2013 dues paid before sponsoring a late-breaking abstract.) 16 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  19. 19. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 17 Disclosure of Chemical Structures The Program Committee will then Each abstract should contain: (a) an evaluate the information provided by introductory sentence indicating the At the time of abstract submission, the corresponding author and purposes of the study; (b) a brief the submitting author is required to determine the acceptability of the description of pertinent state whether chemical compounds proffered paper for presentation. experimental procedures; (c) a were used in the scientific work to Those who do not intend to disclose summary of the new, unpublished generate the data in the proffered chemical structures may have their data; and (d) a statement of the paper. Chemical compounds are abstracts rejected for participation; conclusions. defined as low-molecular-weight however, a limited number of these (generally <1000 g/mol) organic or abstracts may be accepted for Authors must accept sole inorganic molecules, peptides, or presentation if deemed to be of responsibility for the statements in proteins/nucleic acids co-crystallized sufficient scientific merit. their abstracts. Abstracts should be with low-molecular-weight molecules. carefully proofread to avoid errors in the published literature. American If chemical compounds were used, spelling should be used throughout; the corresponding author is further Content of Abstracts for more information regarding required to indicate whether the American spelling, please refer to complete chemical structures of the Authors who submit abstracts Scientific Style and Format: The compounds used will be disclosed confirm that they have not CSE Manual for Authors, Editors, at the time of presentation at the previously published these data, and Publishers, Seventh Edition meeting. The chemical structures that they have not previously (Council of Science Editors, 2006). are not required to be included at presented them at another large the time of abstract submission; national annual scientific meeting, rather, an indication of the intent to and that they are not planning to disclose any such structures at the present or publish them prior to time of presentation is required. the dates of the AACR Annual Meeting 2013. 17
  20. 20. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 18 gUiDEliNES FOR PREPARATiON AND SUBMiSSiON OF ABSTRACTS Spotlight on Clinical Research The AACR Annual Meeting is the data and one explaining the science translational implications will be premier event for presenting driving the clinical trials. In addition to considered for inclusion in this series cutting-edge cancer research covering providing a greater understanding of of sessions focused on clinical trials. the spectrum of science from the the science, this format provides bench to the clinic. The Annual increased opportunities for Abstracts submitted for both the Meeting 2012 reinforced the AACR’s presentation. Presenters of selected regular or the late-breaking deadlines long-standing commitment of abstracts will be asked to describe the will be considered by the Program highlighting the best science-based science informing the development of Committee. Placeholder abstracts may clinical research by featuring an the novel agent and/or diagnostic and be submitted by the January 28 unprecedented four clinical trials the clinical trial. late-breaking abstract deadline for sessions. These sessions were very clinical trials that only have preliminary well received, often attracting A specially appointed committee will data at the time of submission with standing-room-only crowds. Based review and select abstracts focused on final results to be submitted by March upon this success, in 2013 we will preclinical research and Phase I, II, and 1, 2013. The process for submitting a continue to provide many opportunities III clinical trials in treatment and placeholder is detailed on page 19. for our attendees to feature their prevention to be highlighted as clinical research in Clinical Trials proffered oral presentations. All clinical Symposia, poster sessions, and the trials-related abstracts submitted Clinical Trials in Progress poster within the Clinical Research (CL) session. This Symposium presentation category and any preclinical format, which is detailed below, subcategory that has significant provides the scientific context in which the clinical trials are designed and performed. Cutting-edge clinical trials selected for oral presentation will consist of separate talks: one featuring the trial 18 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  21. 21. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 19 Placeholder Abstracts for • A placeholder abstract category The submission of abstracts in Clinical Trials (PL01: Phase I Clinical Trial Data: accordance with these guidelines Placeholder; PL02: Phase II Clinical does not guarantee acceptance by In an effort to ensure that the latest Trial Data: Placeholder, or PL03: the special subcommittee. All and most exciting new data in clinical Phase III Clinical Trials Data: late-breaking and placeholder trials is presented at the Annual Placeholder) must be selected in the abstracts must be submitted online. Meeting 2013, the AACR has online abstract submitter. Complete instructions for preparing implemented a special policy for the and submitting these abstracts will be submission of late-breaking abstracts • Abstracts must include the following available in January 2013 at of clinical trials for which only information: preliminary data are available at the time of the late-breaking abstract • Objectives of the study deadline of January 28, 2013. • Methodology Clinical Trials in Progress Poster To be eligible for consideration, the Session • Preliminary data or an indication following guidelines must be strictly of the type of results anticipated. Abstracts submitted to the Clinical followed: (This is especially applicable to Trials in Progress (CL15) category • Abbreviated abstracts must be clinical trials that are about to should summarize promising ongoing submitted by the late-breaking be closed.) trials that have not yet yielded final abstract submission deadline of results. A designated area of the • Completed abstracts including all January 28, 2013, and must also poster hall will be dedicated to the data—that is, Results and comply with the rules specified for presentation and discussion of Conclusions—must be submitted by their submission. abstracts accepted to this category. the final deadline of March 1, 2013. Press Coverage at AACR Annual Meetings Growing interest by the general public • More than 21 trillion media ABC World News Tonight, CBS in all areas of cancer research, impressions resulted from press Evening News, U.S. News & World especially patient-centered clinical coverage of hot topics in 2012, up Report, The Washington Post, CNN, information, has led to an increase in from 3 billion in 2011 BBC, Nature, Oncology Times, press coverage at AACR Annual and more Meetings. • There was press coverage of the Opening Plenary and other Plenary • Major outlets featured extensive • Over 110 press representatives were Sessions in major media outlets press coverage of clinical trials present onsite, and nearly 30 including The Wall Street Journal, such as BATTLE and STAR, which attended by teleconference The New York Times, Time were presented in major scientific Magazine, Los Angeles Times, USA sessions Today, NBC Today Show Online, 19
  22. 22. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 20 gUiDEliNES FOR PREPARATiON AND SUBMiSSiON OF ABSTRACTS MCB Molecular and Cellular Biology MCB1 Cell Growth Signaling Pathways Growth factors Receptors Cell signaling Tumor-stromal cell interactions Cell-cell interactions Cell and tissue kinetics Protein and lipid kinases Protein and lipid phosphatases GTPases, their regulators, and effectors Ubiquitin and ubiquitin-like proteins Protein acetylation Protein trafficking Cell polarity Signaling and new technologies Other MCB2 Cell Death Transcriptional control of apoptosis Cell death receptors/apoptotic signaling pathways Caspases Effectors of apoptosis Abstract Categories 2013 Regulators of apoptosis Enhancement of apoptosis by chemotherapeutic agents The 2013 abstract categories, along with their related subcategories Survival factors and subclassifications, are presented for your information in this bcl-2 family proteins: Anti- and proapoptotic section. When you use the Online Abstract Submission System, Autophagy and cell death Necrosis and necroptosis these options are available for your selection. Authors are asked to Other choose the appropriate category, subcategory, and subclassification MCB3 Molecular Genetics that best describe the scientific content of the abstract and the Molecular marker studies particular scientific audience you wish to reach. This information will Functional identification of new cancer genes be used as a guide by the members of the Program Committee in Cloning of cancer genes their review of abstracts and planning of sessions at the 2013 Molecular cytogenetics Mutation detection methods Annual Meeting. Please note that these abstract categories may or Other may not be used as Annual Meeting session titles. There is some MCB4 Oncogenes and Tumor Suppressor Genes intentional duplication of topics across categories. Before making Oncogene growth factors and their receptors your selection, please scan the entire list for the most appropriate Tumor suppressor genes abstract category, subcategory, and subclassification. Cytoplasmic signal transducers (ras, raf, MAPK regulators, apoptosis regulators, etc.) Nuclear oncoproteins and tumor suppressor genes Genotype/phenotype correlations Other MCB5 Gene Regulation and Transcription Factors Gene expression Chromatin structure and function Mechanisms of transcription Oncogenic transcription factors Promoters and enhancers of transcription Protein-protein interactions in transcription factor function RNA interference Transcriptional control of cell differentiation Posttranscriptional and translational control Regulation of transcription factor function Other 20 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012
  23. 23. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 21 MCB6 Epigenetics MCB11 Bioinformatics and Computational TB Tumor Biology Chromatin structure and function Molecular Biology DNA methylation Gene expression profiling DNA methylation inhibitors Sequence analysis Epigenetic changes as molecular New algorithms TB1 Cell Culture and Animal markers of cancer Unique database resources Models of Cancer Gene silencing Molecular modeling Mouse models of human cancer Genomic imprinting New software for data analysis Human-in-mouse models of Histone acetylation Mathematical modeling human cancer Histone methylation Application of bioinformatics 3-D and tissue recombinant models Other to cancer biology Noninvasive imaging in animal models Other Developmental phenotypes of MCB7 Cell Cycle cancer genes Control of cell cycle progression MCB12 Innovative Technologies in Model organisms in drug discovery Cell cycle checkpoints Cancer Research Zebrafish models of cancer Cyclins Tumor microdissection Other animal and cell models CDKs and CDK inhibitors Sequencing of cancer Mitosis Microarrays Other Cytokinesis Proteomics Phosphorylation and proteolysis Metabolomics TB2 Stem Cell Biology/ in cell cycle control Imaging Cancer Stem Cells/ Negative cell cycle regulators Other Developmental Oncobiology Quiescence Adult stem cells DNA synthesis MCB13 microRNAs and Embryonic stem cells Telomeres and telomerase Other Noncoding RNAs Stem cell markers Other miRNA regulation of cancer biology Stem-cell-based therapies miRNAs as tumor Cancer stem cells MCB8 DNA Damage and Repair suppressors/oncogenes Developmental pathways in cancer Gene amplification miRNA profiling in cancer Other Non-homologous end joining Epigenetic control of Homologous recombination miRNA expression TB3 Tumor Adhesion Transcription-coupled repair Ultraconserved region-derived Cell adhesion and extracellular matrix Chromosomal structural small RNAs Cell-cell adhesion alterations/translocations Noncoding RNAs In vitro models of tumor adhesion Genomic instability Genetics of miRNA and/or other Reconstituted basement membrane Mechanisms of genomic alterations noncoding RNAs 3-D models Viral mechanisms affecting miRNA-based diagnostics Drug resistance DNA damage and repair miRNA-based therapeutics Other Other Other TB4 Tumor Metastasis MCB9 Metabolism and Cancer MCB14 Cancer Systems Biology Biomarkers of tumor metastasis Autophagy Integrative cancer biology Detection of occult metastases Signaling pathways that Synthetic biology Epithelial/mesenchymal transition regulate metabolism Network biology Expression profiling of tumor Metabolic pathways Biological systems engineering progression and metastasis Mitochondrial function Complex dynamical systems Imaging of tumor progression Energy kinetics Computational systems biology and metastasis Metabolic interactions between Systems modeling Metastasis and the tumor epithelial and stromal cells Control theory microenvironment Warburg effect Other Metastasis-promoting genes Other Metastasis suppressor genes MCB15 Cellular Stress Responses CTC/DTC detection MCB10 Genomics Oxidative stress Premetastatic niche Genomic profiling of tumors Anoikis Comparisons of the tumor stem cell Computational tools and databases Senescence niche at the primary versus the Functional genomics Aging metastatic site High-throughput biology Telomere shortening Other Large-scale approaches to Hypoxia cancer gene discovery Unfolded protein response Single cell cancer genomics Other Tumor evolution Other 21
  24. 24. 13AM_CFA_text_Layout 1 8/28/12 12:33 PM Page 22 TB5 Angiogenesis, Vasculogenesis, TB8 Pediatric Cancer - Basic Science Mutagenesis Microcirculation, and (See also CL4: Pediatric Cancer - Predictive assays for carcinogenicity Cellular Microenvironment Clinical Investigations.) Premalignant lesions Angiogenesis inhibitors Preclinical pediatric research Reactive oxygen studies/ Endothelial cell functions Genetics/genomics/epigenetics of oxidative stress in vitro and in vivo pediatric cancer Signal transduction Host-tumor interactions Stem cells and tumors of the Toxicology Molecular mechanisms developing nervous system Tumor promotion of angiogenesis Targeting developmental signaling Other Novel pro- and antiangiogenic factors pathways in cancer Tumor microcirculation and Animal models of pediatric disease the microenvironment Pediatric cancer cell death Antiangiogenic kinase inhibitors mechanisms and regulation CH Cancer Chemistry Metronomic therapy Pediatric cancer biomarkers Pericyte biology Other Resistance to angiogenesis inhibitors CH1 Drug Discovery and Design VEGF/VEGF receptors TB9 Radiation Biology Drug design Vasculogenesis (See also CL10: Radiation Oncology.) Lead identification Other ATM/ATR Lead optimization Cell cycle and apoptosis in Natural products TB6 Tumor Microenvironment radiation responses Chemoinformatics, in silico screening, Immunity and the microenvironment Cytokines in radiation response and computational methods Epigenetic responses to and from DNA damage and repair High-throughput screening the microenvironment and mutagenesis (assays and libraries) Extracellular matrix and integrins Molecular modulators of Basic and applied nanotechnology Chemokines in the microenvironment radiation response and therapeutics Drug targets in the microenvironment Oncogenes and tumor suppressor Synthesis, metabolism, Gene expression in genes in radiation responses and disposition the microenvironment Photobiology/photodynamic therapy Drug delivery Inflammatory cells as regulators Radiation-induced Other of tumor growth biochemical alterations Immune cells in the tumor Radiation-induced gene expression CH2 Structural and Chemical Biology microenvironment Radiation resistance Small molecule, protein, and Proteases and inhibitors Radioprotectors and radiosensitizers nucleic acid interactions in the microenvironment Radiation-activated X-ray and NMR structures Organ-specific microenvironments signaling pathways Chemical genetics, genomics, Regulators in body fluids (plasma, Other and glycomics CSF, ductal secretions) Target identification, small molecule Tumor-stromal interactions TB10 Migration and Invasion probes, and libraries Tumor/wound relationships Migration Nanotechnology in chemical biology Microbiome Invasion Other Mechanotransduction (ECM stiffness) Polarity Tumor dormancy Actin cytoskeleton CH3 Proteomics, Metabolomics, and Tumor-immune system interactions Microtubules Biological Mass Spectrometry Microvessicles/exosomes, Ameboid and mesenchymal migration Proteomics and biomarker discovery including gap junctions Collective migration Proteomics and signaling networks Microenvironment-induced Models of migration and invasion Biological mass spectrometry therapeutic resistance Genes that regulate migration and systems biology Other and invasion Other Other TB7 In Vivo Imaging CH4 Chemical Aspects of Imaging of molecular and cellular Carcinogenesis events in tumors and tumor cells Nucleic acid damage Imaging of molecular and CG Carcinogenesis Carcinogen metabolism cellular events in the and disposition tumor microenvironment Oxidative stress and inflammation Imaging in animal models CG1 Carcinogenesis – Chemical, Other Imaging the immune response Viral, and Radiation Imaging tumor metabolism CH5 Imaging Agents and Immune suppression New targets for imaging Radiotherapeutics and carcinogenesis Application of imaging technology Imaging agents and radiotherapeutics Animal and in vitro models to the clinic Other for carcinogenesis Advanced nanotechnology DNA damage and repair CH6 Drug Delivery and imaging Molecular carcinogenesis Basic and applied nanotechnology Other Chemical carcinogenesis and therapeutics Environmental carcinogenesis Other Viral-induced transformation Host-virus interactions Hormonal carcinogenesis Radiation carcinogenesis 22 AACR ANNUAL MEETING 2013 Abstract Submission Deadline: November 15, 2012